The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.

The more things change, the more they stay the same. The satirical 19th-century French critic Jean-Baptiste Alphonse Karr wasn't channeling ophthalmology when he authored that truism in 1849. But the comment applies, nonetheless.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet